HIGHLIGHTS
- What: An advanced HCC patient, initially deemed unsuitable for standard treatment, demonstrated remarkable improvement after receiving combined immune therapy, which was subsequently followed by standard treatment.
- Who: Hisashi Nagai and collaborators from the Human and Environmental Studies, Tokai University, Kanagawa, JPN Oncology, Ginza Phoenix Clinic, Tokyo, JPN have published the research work: Review began 07/19/2024 Review ended 07/26/2024 Published 08/05/2024 © Copyright, in the Journal: (JOURNAL) of August/05,/2024
SUMMARY
The landscape of cancer immunotherapy is constantly evolving with innovative treatments that harness the body . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.